Comparative Pharmacology
Head-to-head clinical analysis: AMOXICILLIN PEDIATRIC versus AMOXICILLIN CLAVULANATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMOXICILLIN PEDIATRIC versus AMOXICILLIN CLAVULANATE.
AMOXICILLIN PEDIATRIC vs Amoxicillin-Clavulanate
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Amoxicillin is a semisynthetic penicillin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs). It blocks the transpeptidation step in peptidoglycan cross-linking, leading to cell lysis and death.
Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and autolysin inhibitors. Clavulanate is a beta-lactamase inhibitor that binds to and inactivates beta-lactamases, protecting amoxicillin from hydrolysis.
Treatment of infections caused by susceptible strains of microorganisms in conditions such as otitis media, sinusitis, pharyngitis, tonsillitis, pneumonia, bronchitis, urinary tract infections, skin and skin structure infections, and gonorrheaProphylaxis of infective endocarditis in patients undergoing dental or upper respiratory tract procedures (off-label but per ADA/AHA guidelines)Eradication of Helicobacter pylori (as part of combination therapy)
Acute bacterial sinusitisAcute otitis mediaCommunity-acquired pneumoniaUrinary tract infectionsSkin and skin structure infectionsIntra-abdominal infectionsLower respiratory tract infectionsDiabetic foot infectionsProphylaxis of infection following surgery (off-label)
250-500 mg orally every 8 hours or 500-875 mg orally every 12 hours for adults.
500 mg/125 mg orally every 8 hours or 875 mg/125 mg orally every 12 hours; intravenous: 1 g/0.2 g every 8 hours.
None Documented
None Documented
Terminal elimination half-life: 1-1.5 hours in children with normal renal function; prolonged to 7-21 hours in anuria.
Amoxicillin: ~1-1.3 hours in adults with normal renal function; Clavulanate: ~1 hour. Both prolonged in renal impairment (amoxicillin up to 7-20 hours with CrCl <10 mL/min).
Amoxicillin is primarily metabolized by hydrolysis to penicilloic acid, which is then excreted renally. It does not undergo extensive hepatic metabolism; renal clearance involves tubular secretion and glomerular filtration.
Amoxicillin is partially metabolized via hydrolysis of the beta-lactam ring to inactive penicilloic acid, minor hepatic metabolism; excreted primarily unchanged renally. Clavulanate is extensively metabolized in the liver, primarily to metabolites excreted in urine and feces.
Renal: 60-80% unchanged via glomerular filtration and tubular secretion; biliary: minor (<10%); fecal: <5%.
Amoxicillin: ~60% renal as unchanged drug via glomerular filtration and tubular secretion; Clavulanate: ~30-50% renal as metabolites and unchanged, remainder fecal. Approximately 50-70% of total dose excreted renally within 6 hours.
17-20% bound to serum proteins, primarily albumin.
Amoxicillin: ~17% bound to serum protein (primarily albumin); Clavulanate: ~25% bound to albumin.
0.3-0.5 L/kg; reflects distribution into extracellular fluid and well-perfused tissues; crosses placenta and distributes into pleural, synovial, and peritoneal fluids.
Amoxicillin: Vd ~0.3-0.4 L/kg; clavulanate: Vd ~0.3 L/kg. Distributes well into interstitial fluid, tissues, and bone; limited CNS penetration (10-20% of serum levels) unless inflamed meninges.
Oral: 75-90% (absorption is rapid but incomplete; food does not significantly affect absorption).
Oral: 80-90% for both components; food does not significantly affect absorption (note: clavulanate is better absorbed with food, extended-release tab with food).
CrCl 10-30 mL/min: administer every 12 hours. CrCl <10 mL/min: administer every 24 hours. Hemodialysis: administer dose after dialysis.
CrCl 30-50 mL/min: 500 mg/125 mg orally every 12 hours; CrCl 10-29 mL/min: 500 mg/125 mg orally every 24 hours; CrCl <10 mL/min: 500 mg/125 mg orally every 24 hours, supplement after dialysis.
No specific dose adjustment required for Child-Pugh A or B. Child-Pugh C: consider dose reduction based on clinical response.
No specific adjustment recommended; use with caution in severe hepatic impairment (Child-Pugh C).
Neonates <4 weeks: 30 mg/kg/day divided every 12 hours. Infants and children >4 weeks: 20-50 mg/kg/day divided every 8 hours (mild-moderate infection) up to 80-100 mg/kg/day divided every 6-8 hours (severe infection).
3 months to 40 kg: 25-45 mg/kg/day of amoxicillin component in 2-3 divided doses; >40 kg: adult dosing.
No specific dose adjustment based solely on age; assess renal function and adjust accordingly due to age-related decline in GFR.
Adjust based on renal function; initiate with lower end of dosing due to age-related renal decline.
No FDA black box warning.
None
Serious hypersensitivity reactions (anaphylaxis) may occur; discontinue therapy if allergic reaction occurs. Clostridium difficile-associated diarrhea (CDAD) can occur. Adjust dose in renal impairment. Use caution in patients with mononucleosis due to high incidence of morbilliform rash. Prolonged use may result in superinfection.
["Serious hypersensitivity reactions (anaphylaxis) can occur","Clostridium difficile-associated diarrhea (CDAD) risk","Hepatic dysfunction, including hepatitis and cholestatic jaundice, especially in elderly and patients with prior therapy","Renal impairment requires dose adjustment","Potential for superinfection with prolonged therapy"]
Hypersensitivity to amoxicillin or any penicillin derivative; history of anaphylactic reaction to beta-lactams.
["History of hypersensitivity reaction to any penicillin","History of cholestatic jaundice or hepatic dysfunction associated with amoxicillin-clavulanate","Infectious mononucleosis (risk of erythematous rash)"]
Data Pending Review
Data Pending Review
Amoxicillin absorption is not significantly affected by food; may be taken with or without meals. However, to minimize gastrointestinal upset, administer with a small amount of food if needed. Avoid acidic beverages (e.g., fruit juices) within 1 hour of dosing as they may degrade the antibiotic.
May be taken with food to reduce GI irritation. No significant food interactions. Avoid high-fat meals if taking extended-release formulation (fat increases absorption variability).
Amoxicillin is classified as FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Human data from pregnant women indicate no increased risk of major birth defects across all trimesters. Caution in first trimester due to limited data, but generally considered safe.
FDA Category B. No evidence of teratogenicity in animal studies; human data do not indicate increased risk of major birth defects. However, use only when clearly needed in pregnancy, especially during first trimester. Theoretical risk of neonatal kernicterus if used near term due to bilirubin displacement from albumin.
Amoxicillin is excreted into breast milk in low concentrations (M/P ratio approximately 0.01-0.02). Considered compatible with breastfeeding; minimal risk of infant effects such as diarrhea or allergic sensitization. Monitor infant for potential gastrointestinal disturbances.
Compatible with breastfeeding. Excreted into breast milk in low amounts (M/P ratio not established; amoxicillin milk concentration ~ 0.5-1% of maternal serum). No adverse effects reported in nursing infants. Consider monitoring for diarrhea or rash.
Physiologic changes in pregnancy (increased renal blood flow, glomerular filtration rate, and volume of distribution) may lower serum concentrations. Standard dosing is generally adequate, but severe infections may require dose adjustment. No specific dose reduction recommended; monitor clinical response.
No routine dose adjustment in pregnancy despite increased renal clearance and expanded plasma volume. Standard adult dosing is appropriate unless GFR <30 mL/min. Monitor for therapeutic efficacy in pregnancy-related infections (e.g., UTIs, chorioamnionitis).
Category A/B
Category C
Amoxicillin pediatric suspension is dosed based on body weight; typical dose is 20-40 mg/kg/day in divided doses every 8 hours. For high-dose therapy (e.g., resistant pneumococcus), 80-90 mg/kg/day in two divided doses. Shake suspension well before each dose. Use within 14 days after reconstitution; discard unused portion. Not for patients with severe renal impairment (CrCl <30 mL/min) without dose adjustment. Monitor for rash, diarrhea, and hypersensitivity reactions.
Administer with food to reduce GI upset. Monitor for rash, especially in patients with mononucleosis (EBV). Dose adjustment required for CrCl <30 mL/min. High dose (2000 mg amoxicillin) provides adequate coverage for penicillin-resistant S. pneumoniae. Avoid in penicillin allergy; cross-reactivity with cephalosporins is low but possible.
Take this medication exactly as prescribed; complete the full course even if your child feels better.Shake the bottle well before each dose; measure the dose with the provided dosing device.Refrigerate the suspension after mixing; do not freeze. Discard any unused portion after 14 days.Do not give this medication if your child is allergic to penicillins or cephalosporins.Common side effects include diarrhea, nausea, and rash. Contact your doctor if severe diarrhea or signs of allergic reaction occur.This medication may reduce the effectiveness of oral contraceptives; use additional birth control if applicable.Inform your doctor if your child has kidney disease, phenylketonuria (some suspensions contain phenylalanine), or is pregnant/breastfeeding.
Take with food or milk to minimize stomach upset.Complete the full course even if you feel better.Shake oral suspension well before each use.Use backup contraception if on oral contraceptives.Contact doctor if rash, watery diarrhea, or signs of liver problems (yellowing skin, dark urine).Do not take if allergic to penicillin or cephalosporins.